{"id":689190,"date":"2026-04-25T10:06:03","date_gmt":"2026-04-25T10:06:03","guid":{"rendered":"https:\/\/microscopemedia.com\/?p=689190"},"modified":"2026-04-25T10:06:03","modified_gmt":"2026-04-25T10:06:03","slug":"apar-medicamente-mai-ieftine-pentru-boli-de-ochi-europa-va-economisi-747-milioane-de-euro","status":"publish","type":"post","link":"https:\/\/microscopemedia.com\/?p=689190","title":{"rendered":"Apar medicamente mai ieftine pentru boli de ochi: Europa va economisi 747 milioane de euro"},"content":{"rendered":"
<\/div>\n

Pia\u021ba oftalmologic\u0103 intr\u0103 \u00eentr-o nou\u0103 etap\u0103. Apari\u021bia primelor biosimilare (medicamente biologice ale unor terapii care \u0219i-au pierdut brevetul) ale afliberceptului \u00een Europa va reduce cheltuielile din s\u0103n\u0103tate cu p\u00e2n\u0103 la 747 milioane de euro p\u00e2n\u0103 \u00een 2031, potrivit unui raport al consultan\u021bei IQVIA. Laboratoare precum Sandoz, Biocon \u0219i Celltrion \u00ee\u0219i vor lansa propriile versiuni, noteaz\u0103 El Economista.<\/a><\/p>\n

Introducerea acestor biosimilare se contureaz\u0103 ca una dintre cele mai importante schimb\u0103ri economice pentru sistemele de s\u0103n\u0103tate europene. Molecula este utilizat\u0103 \u00een tratarea mai multor boli oftalmologice ale retinei, \u00een special degenerescen\u021ba macular\u0103 legat\u0103 de v\u00e2rst\u0103 \u0219i edemul macular diabetic. Aceste afec\u021biuni sunt \u00een cre\u0219tere, pe fondul \u00eemb\u0103tr\u00e2nirii popula\u021biei.<\/p>\n

Eylea, produs de Bayer, a generat 3.11 miliarde de euro \u00een 2025<\/h2>\n

Medicamentul original este Eylea, produs de Bayer. Acesta a generat venituri de 3,11 miliarde de euro \u00een 2025, \u00een sc\u0103dere cu 5,9% fa\u021b\u0103 de anul anterior, conform rezultatelor financiare ale companiei. Tratamentul a \u00eenceput s\u0103 piard\u0103 protec\u021bia brevetului \u00een Europa \u00een 2023, iar exclusivitatea a expirat treptat \u00eentre 2024 \u0219i 2026, odat\u0103 cu aprobarea biosimilarelor.<\/p>\n

Medicamentele biologice sunt costisitoare \u0219i reprezint\u0103 o provocare pentru bugetele sistemelor de s\u0103n\u0103tate. Acestea au reprezentat peste 40% din cheltuielile farmaceutice totale \u00een Uniunea European\u0103 \u00een 2023 \u0219i 2024, \u00een cre\u0219tere fa\u021b\u0103 de 28% \u00een 2014, potrivit raportului.<\/p>\n

Sandoz, unul dintre principalii actori prin lansarea Afqlir<\/h2>\n

Primul juc\u0103tor care a f\u0103cut un pas important \u00een Europa este Sandoz, devenind unul dintre principalii actori prin lansarea Afqlir. Dup\u0103 autorizarea acordat\u0103 de Agen\u021bia European\u0103 a Medicamentului, compania a \u00eenceput distribu\u021bia \u00een principalele pie\u021be europene.<\/p>\n

Celltrion \u0219i Biocon sunt, de asemenea, printre actorii importan\u021bi ai acestei noi etape \u00een tratamentul bolilor retiniene. Companiile au ob\u021binut aprobarea european\u0103 pentru biosimilarele lor de aflibercept \u0219i preg\u0103tesc lansarea comercial\u0103.<\/p>\n

Samsung Bioepis vrea s\u0103 devin\u0103 lider pe aceast\u0103 pia\u021b\u0103. Dup\u0103 experien\u021ba cu ranibizumab, primele biosimilare lansate \u00een oftalmologie, compania a ob\u021binut autoriza\u021bia european\u0103 \u0219i se preg\u0103te\u0219te s\u0103 intre pe pia\u021b\u0103.<\/p>\n

\u00centre 2024 \u0219i 2030, se estimeaz\u0103 c\u0103 69 de medicamente biologice \u00ee\u0219i vor pierde brevetul \u00een Europa, dublu fa\u021b\u0103 de ultimii \u0219apte ani. Cu toate acestea, doar 29% dintre aceste molecule au biosimilare \u00een dezvoltare.<\/p>\n","protected":false},"excerpt":{"rendered":"

Pia\u021ba oftalmologic\u0103 intr\u0103 \u00eentr-o nou\u0103 etap\u0103. Apari\u021bia primelor biosimilare (medicamente biologice ale unor terapii care \u0219i-au pierdut brevetul) ale afliberceptului \u00een Europa va reduce cheltuielile din s\u0103n\u0103tate cu p\u00e2n\u0103 la … Read More<\/a><\/p>\n","protected":false},"author":1,"featured_media":689191,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"Default","format":"standard","meta":[],"categories":[1],"tags":[],"_links":{"self":[{"href":"https:\/\/microscopemedia.com\/index.php?rest_route=\/wp\/v2\/posts\/689190"}],"collection":[{"href":"https:\/\/microscopemedia.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/microscopemedia.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/microscopemedia.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/microscopemedia.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=689190"}],"version-history":[{"count":0,"href":"https:\/\/microscopemedia.com\/index.php?rest_route=\/wp\/v2\/posts\/689190\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/microscopemedia.com\/index.php?rest_route=\/wp\/v2\/media\/689191"}],"wp:attachment":[{"href":"https:\/\/microscopemedia.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=689190"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/microscopemedia.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=689190"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/microscopemedia.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=689190"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}